MA41778A - Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine - Google Patents

Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Info

Publication number
MA41778A
MA41778A MA041778A MA41778A MA41778A MA 41778 A MA41778 A MA 41778A MA 041778 A MA041778 A MA 041778A MA 41778 A MA41778 A MA 41778A MA 41778 A MA41778 A MA 41778A
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
bromodomain inhibitors
compounds
formula
salts
Prior art date
Application number
MA041778A
Other languages
English (en)
Inventor
Rino Antonio Bit
John Alexander Brown
Philip G Humphreys
Katherine Louise Jones
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA41778A publication Critical patent/MA41778A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

Composés de formule (i) et leurs sels: dans lesquels r1, r2, r3, r4 sont définis ici. Les composés de formule (i) et leurs sels inhibent la liaison de la famille bet des protéines de bromodomaïne à, par exemple, des résidus de lysine acétylés et peuvent donc être utilisés en thérapie, par exemple dans le traitement de maladies auto-immunes et inflammatoires, comme la polyarthrite rhumatoïde; et les cancers.
MA041778A 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine MA41778A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1504689.9A GB201504689D0 (en) 2015-03-19 2015-03-19 Chemical compounds

Publications (1)

Publication Number Publication Date
MA41778A true MA41778A (fr) 2018-01-24

Family

ID=53052091

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046981A MA46981A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA041778A MA41778A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA046981A MA46981A (fr) 2015-03-19 2016-03-17 Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine

Country Status (35)

Country Link
US (2) US10442786B2 (fr)
EP (2) EP3271349B1 (fr)
JP (1) JP6419990B2 (fr)
KR (1) KR102072850B1 (fr)
CN (1) CN107635989B (fr)
AR (1) AR103934A1 (fr)
AU (1) AU2016232217B2 (fr)
BR (1) BR112017019779B1 (fr)
CA (1) CA2979504C (fr)
CL (1) CL2017002332A1 (fr)
CO (1) CO2017009992A2 (fr)
CR (1) CR20170430A (fr)
CY (1) CY1121855T1 (fr)
DK (1) DK3271349T3 (fr)
DO (1) DOP2017000213A (fr)
EA (1) EA033594B1 (fr)
ES (1) ES2735417T3 (fr)
GB (1) GB201504689D0 (fr)
HR (1) HRP20191186T1 (fr)
HU (1) HUE044414T2 (fr)
IL (1) IL254318B (fr)
LT (1) LT3271349T (fr)
MA (2) MA46981A (fr)
ME (1) ME03485B (fr)
MX (1) MX2017012023A (fr)
PE (1) PE20180032A1 (fr)
PH (1) PH12017501620A1 (fr)
PL (1) PL3271349T3 (fr)
PT (1) PT3271349T (fr)
RS (1) RS59056B1 (fr)
SG (1) SG11201707356QA (fr)
SI (1) SI3271349T1 (fr)
TW (1) TW201706257A (fr)
UY (1) UY36589A (fr)
WO (1) WO2016146738A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR20180039117A (ko) 2015-08-11 2018-04-17 네오메드 인스티튜트 아릴-치환된 디히드로퀴놀리논, 그의 제조법 및 제약으로서의 그의 용도
WO2017024406A1 (fr) 2015-08-11 2017-02-16 Neomed Institute Lactames bicycliques n-substitués, leur préparation et leur utilisation en tant qu'agents pharmaceutiques
US10703740B2 (en) 2015-08-12 2020-07-07 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
EP3612522A4 (fr) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. Composés thérapeutiques
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
JP2021512960A (ja) * 2018-02-06 2021-05-20 シャンハイ ハイファ ファーマシューティカル カンパニー，リミティッド Ｂｅｔ阻害活性を有する化合物並びにその製造方法及び使用
CN109369432B (zh) * 2018-11-02 2021-06-25 永农生物科学有限公司 (s)-4-氯-2-氨基丁酸酯的制备方法
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
EP3937936A4 (fr) * 2019-03-15 2022-12-28 Forma Therapeutics, Inc. Inhibition de la protéine de liaison à un élément sensible à l'amp cyclique (creb)
CN114786675A (zh) * 2019-04-24 2022-07-22 康威基内有限公司 小分子溴结构域抑制剂及其用途
WO2020223370A1 (fr) * 2019-04-29 2020-11-05 The Board Of Regents Of The University Of Texas System Compositions et méthodes de traitement d'infections à schistosomes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
PE20080130A1 (es) 2006-03-31 2008-02-25 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
EP2493310A4 (fr) * 2009-10-27 2014-03-12 Glaxosmithkline Llc Benzimidazoles utilisés en tant qu'inhibiteurs de l'acide gras synthase
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
GB201114103D0 (en) * 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013097052A1 (fr) * 2011-12-30 2013-07-04 Abbott Laboratories Inhibiteurs de bromodomaine
CA2895905A1 (fr) * 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Nouveaux composes heterocycliques en tant qu'inhibiteurs de bromodomaine
DK2970265T3 (en) 2013-03-15 2018-10-01 Plexxikon Inc HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
TWI530499B (zh) 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
TWI527811B (zh) * 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9662311B2 (en) * 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
GB201504694D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate

Also Published As

Publication number Publication date
KR102072850B1 (ko) 2020-02-03
EP3271349A1 (fr) 2018-01-24
JP2018507903A (ja) 2018-03-22
US20200039953A1 (en) 2020-02-06
BR112017019779A2 (pt) 2018-05-22
DK3271349T3 (da) 2019-08-05
PH12017501620A1 (en) 2018-02-12
CN107635989B (zh) 2020-12-08
EA033594B1 (ru) 2019-11-07
JP6419990B2 (ja) 2018-11-07
PE20180032A1 (es) 2018-01-09
PT3271349T (pt) 2019-08-19
DOP2017000213A (es) 2017-10-15
CY1121855T1 (el) 2020-07-31
MX2017012023A (es) 2018-01-30
HUE044414T2 (hu) 2019-10-28
AU2016232217A1 (en) 2017-10-12
LT3271349T (lt) 2019-07-10
AR103934A1 (es) 2017-06-14
CN107635989A (zh) 2018-01-26
CA2979504C (fr) 2023-10-10
US20180044317A1 (en) 2018-02-15
EP3549939A1 (fr) 2019-10-09
SG11201707356QA (en) 2017-10-30
BR112017019779B1 (pt) 2023-10-03
MA46981A (fr) 2019-10-09
CL2017002332A1 (es) 2018-03-16
GB201504689D0 (en) 2015-05-06
IL254318A0 (en) 2017-11-30
HRP20191186T1 (hr) 2019-10-04
PL3271349T3 (pl) 2019-10-31
KR20170129871A (ko) 2017-11-27
ME03485B (fr) 2020-01-20
CO2017009992A2 (es) 2018-01-05
US11053212B2 (en) 2021-07-06
SI3271349T1 (sl) 2019-08-30
EP3271349B1 (fr) 2019-05-15
AU2016232217B2 (en) 2019-04-04
TW201706257A (zh) 2017-02-16
UY36589A (es) 2016-10-31
WO2016146738A1 (fr) 2016-09-22
US10442786B2 (en) 2019-10-15
CA2979504A1 (fr) 2016-09-22
IL254318B (en) 2019-08-29
EA201791973A1 (ru) 2018-07-31
ES2735417T3 (es) 2019-12-18
RS59056B1 (sr) 2019-08-30
CR20170430A (es) 2017-11-08

Similar Documents

Publication Publication Date Title
MA41778A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
EA202092899A1 (ru) Гетероарильные соединения для лечения болезни гентингтона
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202091508A1 (ru) 6-азаиндольные соединения
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201792047A1 (ru) Новые соединения
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
EA201792229A1 (ru) Ингибиторы бромодомена
MA44674B1 (fr) Inhibiteurs de bromodomaine
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
CY1120846T1 (el) 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1
MA41238A (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
EA201990410A1 (ru) Производные имидазола и их применение в лечении аутоиммунных или воспалительных заболеваний или раковых заболеваний
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA202090414A1 (ru) Соединения и их применение
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-